FTSE 100 earnings: why did the AstraZeneca share price fall 7%?

Our writer considers the reasons for AstraZeneca’s fall in the FTSE 100 today and explains why he isn’t too worried as a new shareholder.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s never fun when you invest in a FTSE 100 stock then see it go down almost immediately. That’s what has happened for me with AstraZeneca (LSE: AZN).

After the pharma giant’s full year and Q4 2023 results today (8 February), the share price fell 7% to 9,736p (£97.31). I paid £104 recently.

Why has the market punished the stock?

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALL8 Feb 20198 Feb 2024Zoom ▾Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '242020202020212021202220222023202320242…20242…www.fool.co.uk

The results are in

AstraZeneca was one of the handful of firms that came to the rescue during the pandemic with its Covid vaccine. While that supercharged revenue for a while, Covid-related sales have understandably been falling since.

We can see this in today’s results. Including Covid medicines, full-year revenue totalled $45.8bn, a 6% rise year on year in constant exchange rates. Excluding Covid sales, total revenue jumped 15%.

Since the third quarter, three new medicines were approved. And 12 blockbuster drugs brought in more than $1bn in sales during 2023. Cancer drugs made up 40% of overall revenue.

This helped core full-year earnings per share (EPS) increase 15% to $7.26. However, full-year EBITDA of $13.5bn was around $1bn lighter than analysts’ expectations. This was due to associated costs of new drug launches, higher R&D spending, and some price reductions in emerging markets.

So there was an earnings miss here and the full-year dividend was kept at $2.90 per share.

Why I invested

In the earnings release, chief executive Pascal Soriot said: “We expect another year of strong [double-digit] growth in 2024…Our differentiated and growing portfolio of approved medicines, global reach and rich R&D pipeline give us confidence that we will continue to deliver industry-leading growth.”

This perfectly sums up why I’ve invested. The firm is truly global, with a growing presence in China’s gigantic healthcare market. And its 2021 acquisition of Alexion Pharmaceuticals added treatments for rare diseases, where fewer approved treatment options exist.

Crucially for future growth, it has a huge 178 projects in the pipeline and remains on course for 15 new medicines by 2030.

Finally, I’m excited about artificial intelligence (AI) potentially revolutionising drug discovery over the next decade. AstraZeneca is making major R&D investments in this area.

Valuation

Analysts expect the company to generate EPS of $8.26 in 2024. This forecast puts the forward-looking price-to-earnings (P/E) ratio at around 15.

This compares favourably with peer Merck (17.3) and is a lot cheaper than other healthcare stocks like Novo Nordisk (35).

That said, the stock’s valuation is higher than FTSE 100 peer GSK (10), though that’s largely due to the latter’s litigation problems and lack of new blockbuster drugs.

On balance, I’d say the stock is fairly valued, assuming broker forecasts prove accurate, which isn’t always the case.

One risk I would highlight here though is the redesign of Medicare’s prescription drug coverage in the US, which could hit pharmaceutical profits.

I’m not worried

Ten years ago AstraZeneca set an ambitious target of $45bn in annual revenue by 2023. Having achieved that, it is now embarking on the next 10-year cycle to deliver “superior growth“.

This is how management thinks, in decades, which aligns with my own investing horizon. So I’m not worried by this small setback.

If anything, I’m restraining myself from purchasing more shares. And if I wasn’t already invested, I’d be buying on this dip.

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in AstraZeneca Plc and Novo Nordisk. The Motley Fool UK has recommended AstraZeneca Plc, GSK, and Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Front view of a young couple walking down terraced Street in Whitley Bay in the north-east of England they are heading into the town centre and deciding which shops to go to they are also holding hands and carrying bags over their shoulders.
Investing Articles

Up 15% in a month and still yielding 9.5% – this FTSE second income stock is on fire!

Harvey Jones says wealth manager M&G offers one of the most exciting second income streams on the entire FTSE 100.…

Read more »

Wall Street sign in New York City
Investing Articles

Looking for cheap stocks to buy? 2 reasons now might be the ideal moment!

Amid market turbulence, our writer has not been diving for cover, but actively on the hunt for stocks to buy…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

These 2 FTSE 250 stocks now yield more than 10% – is that income sustainable?

Harvey Jones is astonished to discover how much dividend income investors can get from FTSE 250 stocks. These two have…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

3 promising high-yield FTSE 250 stocks to consider buying right now!

When hunting for lucrative high-yield dividend shares, our writer heads straight for those smaller-caps found in the UK's secondary index,…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

Are Tesla shares now a brilliant long-term opportunity?

Tesla shares have been pummelled by the markets so far this year. Our writer thinks they may have a lot…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Up 22% in a month, has the Rolls-Royce share price restarted its incredible rise?

Even after a storming few years, the Rolls-Royce share price has leapt over a fifth in just one month! Is…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

I’ve been eyeing Nvidia stock, but I just bought this chip giant instead

After a recent fall in the price of Nvidia stock, this writer was considering it but decided to buy a…

Read more »

ISA Individual Savings Account
Investing Articles

Why I don’t hold cash in my Stocks and Shares ISA

Stephen Wright explains why he’s fully invested in his Stocks and Shares ISA – and why he intends to keep…

Read more »